Edition:
United States

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

6.10USD
18 May 2018
Change (% chg)

$0.10 (+1.67%)
Prev Close
$6.00
Open
$6.10
Day's High
$6.30
Day's Low
$5.97
Volume
145,167
Avg. Vol
186,914
52-wk High
$8.55
52-wk Low
$2.45

Chart for

About

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related... (more)

Overall

Beta: 3.63
Market Cap(Mil.): $373.04
Shares Outstanding(Mil.): 62.17
Dividend: --
Yield (%): --

Financials

  ADVM.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -0.98 -- --
ROI: -20.57 -8.07 12.63
ROE: -21.05 -10.87 14.50

BRIEF-Adverum Biotechnologies Reports Q1 Loss Per Share $0.30

* ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Adverum Biotechnologies Announces Leadership Changes

* BOARD AND AMBER SALZMAN, CHIEF EXECUTIVE OFFICER MADE A MUTUAL DETERMINATION THAT SALZMAN STEP DOWN

May 03 2018

BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD

* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD

May 01 2018

BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32

* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 06 2018

BRIEF-Adverum Biotechnologies Prices $60 Mln Public Offering Of Stock

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK

Feb 08 2018

BRIEF-Adverum Biotechnologies Announces Proposed Public Offering

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 07 2018

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

Jan 25 2018

BRIEF-Adverum Biotechnologies Provides 2018 Outlook

* ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017.

Jan 04 2018

BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies

* HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING Source text for Eikon: (http://bit.ly/2iwSEnw) Further company coverage:

Dec 06 2017

BRIEF-Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial

* ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY

Dec 05 2017

Earnings vs. Estimates